{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T09:57:52Z","timestamp":1770458272014,"version":"3.49.0"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The GEPPO project is funded through an independent grant by ViiV Healthcare IT and supported by Penta Foundation"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To investigate the durability of the first integrase inhibitor-based regimen in a HIV geriatric multicentric prospective cohort and to explore the reasons of regimen discontinuation.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Design<\/jats:title>\n<jats:p>This is an analysis conducted on the Geriatric Patients Living with HIV\/AIDS (GEPPO) cohort, an Italian prospective observational multicentre cohort of people living with HIV with 65 years of age or more.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The analysis was performed using R (version 4.0.2). The tests performed were two sided assuming a 5% significance level (Kruskal-Wallis test, Chi-squared test, log-rank test and a Cox Proportional Hazard model). The proportion of participants discontinuing the three regimens was displayed using cumulative curves.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among 1531 patients enrolled between 2017 and 2019 in the GEPPO cohort, we included 822 participants in this analysis. At baseline, median age was 69.8, the immunovirological profile good, multimorbidity was present in 42.3% of participants, while 27.4% were on polypharmacy. Overall, 483, 243 and 96 participants received DTG, RAL and EVG\/c respectively as first InSTI. At the end of the follow up 6.4%, 21.1% and 22.9% participants discontinued DTG, RAL and EVG\/c respectively. Using a log-rank test, EVG showed a significantly lower durability than DTG (p&lt;0.001) or RAL (p 0.05) or both, DTG and RAL (p&lt;0.001). Among participants who discontinued their regimen we found 0 virological failure and 56.7% simplification\/deprescription.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The three integrase inhibitors considered showed a good durability and no virological failures in geriatric patients such as those enrolled in the GEPPO cohort when used in a two or three drug regimen.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0258533","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T18:44:33Z","timestamp":1634150673000},"page":"e0258533","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort"],"prefix":"10.1371","volume":"16","author":[{"given":"Emanuele","family":"Foc\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Calcagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Calza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4467-765X","authenticated-orcid":true,"given":"Stefano","family":"Renzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7109-4399","authenticated-orcid":true,"given":"Annacarla","family":"Chiesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Siano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8774-4843","authenticated-orcid":true,"given":"Giuseppe","family":"De Socio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7058-1048","authenticated-orcid":true,"given":"Stefania","family":"Piconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Orofino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Cattelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Nozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micol","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jovana","family":"Milic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetto Maurizio","family":"Celesia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Guaraldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"issue":"no. 11","key":"pone.0258533.ref001","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1016\/S2352-3018(17)30155-8","article-title":"New HIV diagnoses among adults aged 50 years or older in 31 European countries, 2004\u201315: an analysis of surveillance data","volume":"vol. 4","author":"L. Tavoschi","year":"2017","journal-title":"Lancet HIV"},{"issue":"no. 1","key":"pone.0258533.ref002","first-page":"10","article-title":"The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic Clinical Management of HIV-1 Infected Persons","volume":"vol. 8","author":"G. Guaraldi","year":"2019","journal-title":"J. frailty aging"},{"issue":"2","key":"pone.0258533.ref003","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s41999-019-00170-8","article-title":"European cohorts of older HIV adults: POPPY, AGEhIV, GEPPO, COBRA and FUNCFRAIL","volume":"10","author":"J. Milic","year":"2019","journal-title":"Eur. Geriatr. Med."},{"key":"pone.0258533.ref004","unstructured":"EACS, \u201cEuropean AIDS Clinical Society Guidelines, version 10.1. October 2020,\u201d."},{"key":"pone.0258533.ref005","unstructured":"Department of Health and Human Services, \u201cGuidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV,\u201d 2018. [Online]. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf. [Accessed: 08-Jul-2020]."},{"key":"pone.0258533.ref006","unstructured":"Societ\u00e0 Italiana di Malattie Infettive e Tropicali, Linee Guida Italiane sull\u2019utilizzo della Terapia Antiretrovirale e la gestione diagnostico-clinica delle persone con infezione da HIV-1. 2017."},{"key":"pone.0258533.ref007","article-title":"Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged \u2265 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial","author":"F. Maggiolo","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"pone.0258533.ref008","first-page":"1","article-title":"Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials","author":"F. Spinelli","year":"2021","journal-title":"HIV Res. Clin. Pract."},{"issue":"no. 3","key":"pone.0258533.ref009","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/QAD.0000000000001708","article-title":"Trends in antiretroviral therapy prescription, durability and modification: New drugs, more changes, but less failure","volume":"vol. 32","author":"E. F. Eaton","year":"2018","journal-title":"AIDS"},{"issue":"no. 10","key":"pone.0258533.ref010","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/jac\/dkx169","article-title":"Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study","volume":"vol. 72","author":"S. Nozza","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"no. 99","key":"pone.0258533.ref011","article-title":"The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: A cross sectional study of people aged 65\u201374 years and more than 75 years","volume":"vol. 18","author":"G. Guaraldi","year":"2018","journal-title":"BMC Geriatr."},{"issue":"no. 10","key":"pone.0258533.ref012","doi-asserted-by":"crossref","first-page":"e0222225","DOI":"10.1371\/journal.pone.0222225","article-title":"Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian \u2018GEPPO\u2019 Cohort","volume":"vol. 14","author":"E. Foc\u00e0","year":"2019","journal-title":"PLoS One"},{"issue":"no. 3","key":"pone.0258533.ref013","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/QAI.0000000000001496","article-title":"Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-Infected Patients","volume":"vol. 76","author":"A. Calcagno","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"no. 6","key":"pone.0258533.ref014","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0000000000002853","article-title":"Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV","volume":"vol. 35","author":"G. Guaraldi","year":"2021","journal-title":"AIDS"},{"key":"pone.0258533.ref015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jgar.2019.08.010","article-title":"Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-na\u00efve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety","volume":"vol. 20","author":"V. Cento","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"no. 7","key":"pone.0258533.ref016","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1089\/aid.2018.0006","article-title":"Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience","volume":"vol. 34","author":"M. A. De Francesco","year":"2018","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"pone.0258533.ref017","first-page":"1","article-title":"A patient-centred approach to deprescribing antiretroviral therapy in people living with HIV","author":"G. Guaraldi","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"pone.0258533.ref018","doi-asserted-by":"crossref","first-page":"e25449","DOI":"10.1002\/jia2.25449","article-title":"The challenge of HIV treatment in an era of polypharmacy","volume":"vol. 23","author":"D. Back","year":"2020","journal-title":"JIAS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0258533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T18:45:00Z","timestamp":1634150700000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0258533"}},"subtitle":[],"editor":[{"given":"Alan","family":"Landay","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0258533","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]}}}